Edding Group Company Limited

Our company

Our therapy areas

Career

简繁

The therapeutic area of anti-infectives has a very large patient base in China. We have two flagship originator branded anti-bacterial drugs,Vancocin^® and Ceclor^®.

Our Ceclor^® manufacturing facility is equipped with state-of-the-art equipment, modules and production lines throughout our manufacturing processes, which were imported from globally leading companies from Sweden, Germany and Italy.

Vancocin® (Core product)

Vancocin^®, as the originator-branded product of vancomycin, is the gold standard for treating MRSA infections and is the only first-line drug among major therapies for the treatment of MRSA infections in the NRDL.

Vancomycin hydrochloride for injection Specification:500mg
Ceclor® (Core product)

Cefaclor is one of the leading oral molecules among cephalosporins and has proven safety and efficacy profiles, which are critical for pediatric use. Ceclor^® Sachet is a leading anti-bacterial brand for pediatric use in China.

Cefaclor Sachet Specification:0.125g*6；0.125g*9
Cefaclor Capsules Specification:0.25g*6; 0.25g*12
Cefaclor Sustained Release Tablets (II) Specification:0.375g*4; 0.375g*6; 0.375g*8
Zinacef®

Zinacef ^® is an originator branded cefuroxime product.Cefuroxime is a broadspectrumantibiotic that is used to treat a wide variety of bacterial infections.

Cefuroxime Axetil Tablets Specification:0.25g*6; 0.25g*12
Cefuroxime Sodium for Injection Specification：0.75g
Fortum®

Fortum^®(Ceftazidime for Injection) is an originator-branded anti-infective drug.Ceftazidime is a broad-spectrum antibiotic that is used for the treatment of a number of bacterial infections.

Ceftazidime for Injection Specification: 1g

CVD was China’s third largest therapeutic area in 2022,and there were approximately 330 million CVD patients in China.Statin therapy may reduce the risk of major CV events by approximately only 25% to 35% primarily through lowering LDL-C levels, leaving significant persistent CV risk of approximately 65% to 75%.

Icosapent ethyl (“IPE”) is the first and only drug approved by the FDA as an adjunct to maximally tolerated statin therapy for reducing persistent CV risk in targeted high-risk patients, according to the Frost & Sullivan Report. Vascepa^® received its new drug approval from the FDA in 2012 and was launched in the U.S. in 2013, initially for use as an adjunct to diet to reduce TG.Moreover, Vascepa^® was approved by the FDA for a cardiovascular risk reduction (“CRR”) indication in 2019 as an adjunctive therapy to reduce the risk of cardiovascular events among adults with elevated TG levels (≥150mg/dL). We in-licensed Vascepa^® from Amarin in 2015 for development and commercialization.

Vascepa®

The first and only drug approved by the FDA as an adjunct to maximally tolerated statin therapy for reducing persistent CV risk in targeted high-risk patients.Vascepa^® demonstrated a 25% RRR in the first occurrence of certain MACE in the REDUCE-IT clinical trial. In addition, it has also demonstrated a 20% RRR in CV death.Vascepa^® was approved by the FDA for a CRR indication as an adjunctive therapy to reduce the risk of cardiovascular events among adults with elevated TG levels (≥150 mg/dL).

In May 2023, Vascepa^® received approval from the NMPA for the treatment of severe HTG levels (≥500 mg/dL).As of June 14, 2023, Vascepa^® had already been recommended by seven clinical guidelines in China, including the 2023 China Guidelines for the Management of Blood Lipids.

Respiratory system is one of the fastest-growing and emerging therapeutic areas in China. Both asthma and COPD have strong prevalence in China and have been significantly underdiagnosed and undertreated.The Health China 2030 plan set a target to significantly increase diagnosis rate of COPD and lower the mortality rate of COPD.

ICSs are by far the most effective controller used in the treatment of asthma and one of a few types of drugs that can effectively suppress the characteristic inflammation in asthmatic airways. FPN is the latest-generation ICS nebulizer indicated for the treatment of asthma. Also, we are developing generic versions of two ICS/LABA combination DPI drug, ERC 301 and ERC 302 for treatment of asthma and COPD.

Our respiratory R&D Center in Suzhou, with the robust and proprietary quality management system, is dedicated to ensuring high quality standards of the respiratory products in the future.

Fluticasone Propionate Nebulizer Suspension (Core product)

FPN (Fluticasone Propionate Nebulizer Suspension), is the latest-generation ICS nebulizer indicated for the treatment of mild to moderate asthma in children and adolescents in China.Compared to the only two other types of ICS nebulizers marketed in China as of June 14, 2023, FPN is clinically proven to be more effective and long-lasting，according to the Frost & Sullivan Report.

Fluticasone Propionate Nebulizer Suspension Specification: 2ml:0.5mg
ERC301 & ERC302(pipeline product)

ERC 301 and ERC 302 are generic versions of two ICS/LABA combination DPI drugs that are used for the treatment of asthma and COPD.

There are other branded drugs operating on our platform, covering the area of hematology, nervous system diseases and many other fields，creating a diversified product portfolio to provide more options for Chinese patients.

Mulpleta®

Lusutrombopag（Mulpleta^®） is an innovative thrombopoietin receptor agonist (“TPO-RA”) with the potential breakthrough in the treatment of thrombocytopenia (“TCP”).

NMPA has approved Mulpleta^® (Lusutrombopag Tablets) for the adult patients with chronic liver disease accompany thrombocytopenia who are scheduled to undergo an operation procedure (including diagnostic procedure) (CLD) as an import drug on 27th June 2023. We also plan to explore the indication expansion of Mulpleta^® to CIT（chemotherapy-induced thrombocytopenia）.
EDP 125(pipeline product)

EDP 125 (Edivoxetine) is an innovative selective norepinephrine reuptake inhibitor (“SNRI”) used to treat ADHD.

We have completed the Phase III clinical trial in China for EDP 125 indicated for the treatment of ADHD in children and adolescents in January 2023 and plan to submit NDA to the NMPA in the second half of 2023.
Recormon®

Recombinant Human Erythropoietin ß Injection (CHO Cell) is used for the treatment of cardio-renal-anemia (CRA) syndrome. Recormon^®is the only marketed recombinant human erythropoietin ß injection product in China.

Recombinant Human Erythropoietin β Injection Specification:2,000 IU/0.3ml; 5,000 IU/0.3ml; 10,000 IU/0.6ml
EOC103(pipeline product)

EOC 103 is a novel, oral, selective HDAC inhibitor indicated for the treatment of HR+/HER2- breast cancer.

EOC 103 selectively inhibits Class I HDACs to improve and regulate histone hyperacetylation and promote transcription activation of specific genes, and ultimately inhibit cell proliferation, accelerate terminal differentiation and/or induce apoptosis. EOC 103 has significant advantages over non-selective pan-HDAC inhibitors.
* Information related to relevant industries are based on the Frost & Sullivan Report.

Unit 122-129, Building A3, No. 700, Wanrong Road， Shanghai，China

pr@eddingpharm.com